GDC-6599
Drug Hunter
SEPTEMBER 18, 2023
A First-in-Class TRPA1 Antagonist Overcomes Toxicity Hurdles to Become Cough Candidate Genentech’s GDC-6599 is the first oral TRP Ankyrin 1 (TRPA1) antagonist to reach Ph. IIa ( NCT05660850 ) for chronic cough after preclinical studies and a Ph. I trial showed it was well-tolerated, in contrast to prior molecules. The transient receptor potential (TRP) family of ion channels has been the subject of intensive drug discovery efforts due to their critical role in the development and progression of
Let's personalize your content